Recent Progress in Mass Spectrometry-Based Metabolomics in Major Depressive Disorder Research
Molecules · 04.11.2023 · 28 (21) · 7430
DOI: 10.3390/molecules28217430 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 04.11.2023. Verfasst von Mingxia Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders, National Center for Mental Disorders, Beijing And…. Hauptthemen laut MEDLINE: Major Depressive Disorder. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 166 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the R&D Program of Beijing Municipal Education Commission, the National Natural Science Foundation of China, Beijing Talents Project.
Abstract (Originalsprache)
Major depressive disorder (MDD) is a serious mental illness with a heavy social burden, but its underlying molecular mechanisms remain unclear. Mass spectrometry (MS)-based metabolomics is providing new insights into the heterogeneous pathophysiology, diagnosis, treatment, and prognosis of MDD by revealing multi-parametric biomarker signatures at the metabolite level. In this comprehensive review, recent developments of MS-based metabolomics in MDD research are summarized from the perspective of analytical platforms (liquid chromatography-MS, gas chromatography-MS, supercritical fluid chromatography-MS, etc.), strategies (untargeted, targeted, and pseudotargeted metabolomics), key metabolite changes (monoamine neurotransmitters, amino acids, lipids, etc.), and antidepressant treatments (both western and traditional Chinese medicines). Depression sub-phenotypes, comorbid depression, and multi-omics approaches are also highlighted to stimulate further advances in MS-based metabolomics in the field of MDD research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders, National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing 100088, China.
- Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing 100069, China.
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
ORCID-Profile: Mingxia Liu, Wen Ma
Förderung
- the R&D Program of Beijing Municipal Education Commission
- the National Natural Science Foundation of China
- Beijing Talents Project
- Beijing Key Laboratory of Mental Disorders
- R&D Program of Beijing Municipal Education Commission
- National Natural Science Foundation of China
Zitieren
APA
Liu, M., Ma, W., He, Y., Sun, Z., & Yang, J. (2023). Recent Progress in Mass Spectrometry-Based Metabolomics in Major Depressive Disorder Research. Molecules, 28(21), 7430. https://doi.org/10.3390/molecules28217430
Vancouver
Liu M, Ma W, He Y, Sun Z, Yang J. Recent Progress in Mass Spectrometry-Based Metabolomics in Major Depressive Disorder Research. Molecules. 2023;28(21):7430. doi:10.3390/molecules28217430
BibTeX
@article{Liu2023,
author = {Liu, Mingxia and Ma, Wen and He, Yi and Sun, Zuoli and Yang, Jian},
title = {Recent Progress in Mass Spectrometry-Based Metabolomics in Major Depressive Disorder Research},
journal = {Molecules},
year = {2023},
volume = {28},
number = {21},
pages = {7430},
doi = {10.3390/molecules28217430}
}
EUVIMED